Tulobuterol patch

A technology for adhesives and transdermal absorption preparations, applied in the field of transdermal absorption preparations, can solve problems such as the inability to guarantee consistent release

Inactive Publication Date: 2013-06-05
DAE HWA PHARMA
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This means that consistent drug release for maximum benefit from transdermal formulations cannot be guaranteed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tulobuterol patch
  • Tulobuterol patch

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] 2 mg of tulobuterol was dissolved in 5 mg of absolute ethanol, and then 63 mg of acrylate-vinyl acetate adhesive (Duro-Tak 87-2516, Henkel, USA, solid content 41.5%) was added to prepare a drug layer. The drug layer was coated onto a silicon-treated polyethylene terephthalate film as a peelable film using a laboratory coater (Mathis Co. (Mathis Co., Ltd.), Switzerland), It was made to have a dry thickness of 28 μm, and dried at 80° C. for 10 minutes. The film is coated with polyester as a support and rolled into a transdermal formulation.

Embodiment 2

[0035] 2 mg of tulobuterol was dissolved in 5 mg of absolute ethanol, and then 72 mg of acrylate-vinyl acetate adhesive (Duro-Tak 87-2516, Henkel, USA, solid content 41.5%) was added to prepare a drug layer. The drug layer was coated onto a silicon-treated polyethylene terephthalate film as a peelable film with a laboratory coater (Mathis Co. (Mathis Co., Ltd.), Switzerland) to a dry thickness of 32 μm and dried at 80°C for 10 minutes. The film is coated with polyester as a support and rolled into a transdermal formulation.

Embodiment 3

[0037] 2 mg of tulobuterol was dissolved in 5 mg of absolute ethanol, and then 84 mg of acrylate-vinyl acetate adhesive (Duro-Tak 87-2516, Henkel, USA, solid content 41.5%) was added to prepare a drug layer. The drug layer was coated onto a silicon-treated polyethylene terephthalate film as a peelable film with a laboratory coater (Mathis Co. (Mathis Co., Ltd.), Switzerland) to a dry thickness of 35 μm and dried at 80°C for 10 minutes. The film is coated with polyester as a support and rolled into a transdermal formulation.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention relates to a transdermal absorption preparation with anti-asthmatic drug tulobuterol and salt as active ingredients, in particular to a tulobuterol patch. The transdermal absorption preparation is capable of controlling release of the tulobuterol continuously and has long-term storage stability at the same time, and tulobuterol particles can not be formed on a drug layer.

Description

technical field [0001] The present invention relates to a transdermal absorption preparation comprising tulobuterol (tulobuterol), an anti-asthma drug, as an active ingredient, and in particular relates to a preparation capable of continuously controlling the release of tulobuterol, while having long-term storage stability, and not forming a proper substance in the drug layer. Transdermal formulation of loterol granules. Background technique [0002] Tulobuterol (chemical formula 1) is a drug used in the treatment of chronic bronchitis and asthma. Currently, tulobuterol is marketed as oral and transdermal formulations. However, transdermal formulations are more preferred because oral formulations often have side effects due to a sudden increase in the blood concentration of tulobuterol. [0003] [chemical formula 1] [0004] [0005] Unlike oral formulations, transdermal formulations avoid the problem of hepatic metabolism and enable sustained delivery of active ingred...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/70A61K31/137A61P11/00A61P11/06
Inventor 李汉九黄艳曺永宇朴荣泽
Owner DAE HWA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap